SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
May 02, 2024 16:23 ET | Pomerantz LLP
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised to...
Zymeworks Logo_color.png
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
May 02, 2024 16:05 ET | Zymeworks Inc.
Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of...
Zymeworks Logo_color.png
Zymeworks Announces Participation in Upcoming Investor Conferences
April 30, 2024 06:00 ET | Zymeworks Inc.
VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME 
April 24, 2024 15:28 ET | Pomerantz LLP
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME 
April 16, 2024 15:08 ET | Pomerantz LLP
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised...
Zymeworks Logo_color.png
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
April 11, 2024 06:00 ET | Zymeworks Inc.
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
CARBIOS présente ses
CARBIOS présente ses résultats annuels 2023 et confirme le calendrier 2024 de son déploiement industriel et commercial
April 11, 2024 00:45 ET | Carbios
Solide structure financière du Groupe CARBIOS : position de trésorerie de 192 millions d’euros au 31 décembre 2023Avancée de la construction, en France, de la première usine au monde de...
CARBIOS announces fi
CARBIOS announces fiscal-year 2023 financial results and confirms 2024 calendar for industrial and commercial roll-out
April 11, 2024 00:45 ET | Carbios
CARBIOS Group’s solid financial structure: cash position of €192 million on December 31, 2023Construction progress of world’s first PET1 biorecycling plant in France: in line with delivery...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zymeworks Inc. - ZYME
April 08, 2024 15:08 ET | Pomerantz LLP
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zymeworks Inc. (“Zymeworks” or the “Company”) (NASDAQ: ZYME). Such investors are advised...
Zymeworks Logo_color.png
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
April 08, 2024 06:00 ET | Zymeworks Inc.
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...